Synergistic Melanoma Treatment System

Publication ID: 24-11857529_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Melanoma Treatment System,” Published Technical Disclosure No. 24-11857529_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857529_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,529.

Summary of the Inventive Concept

A novel system integrating dapansutrile administration with AI-powered tumor monitoring, IoT-enabled data transmission, blockchain-based data storage, and nanomaterial-based delivery to provide personalized and effective melanoma treatment.

Background and Problem Solved

The original patent disclosed methods for treating melanoma using dapansutrile. However, these methods had limitations in terms of personalized treatment planning, real-time monitoring, and secure data storage. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system.

Detailed Description of the Inventive Concept

The system comprises a dapansutrile administration module, an AI-powered tumor monitoring module, and a blockchain-based data storage module. The AI-powered tumor monitoring module analyzes tumor size and response to dapansutrile treatment and provides personalized treatment recommendations. The system can also include a wearable device with a dapansutrile sensor, an IoT-enabled data transmission module, and a user interface. Additionally, a blockchain-based platform can be used to track melanoma treatment outcomes, and a nanomaterial-based delivery system can be employed to target dapansutrile delivery to the tumor site.

Novelty and Inventive Step

The new claims introduce the synergistic combination of dapansutrile administration with AI, IoT, blockchain, and nanomaterial-based technologies, which is not obvious from the original patent. The integration of these distinct technologies provides a novel and non-obvious solution for personalized melanoma treatment.

Alternative Embodiments and Variations

Alternative embodiments of the system could include using different AI algorithms, incorporating additional sensors in the wearable device, or employing different nanomaterials for targeted delivery. Variations could also include using the system for treating other types of cancer or integrating with other medical devices.

Potential Commercial Applications and Market

The Synergistic Melanoma Treatment System has significant commercial potential in the oncology market, particularly in the areas of personalized medicine and cancer treatment. The system's ability to provide real-time monitoring and personalized treatment recommendations could lead to improved treatment outcomes and increased patient satisfaction.

Field of Art

Oncology, medical technology, pharmaceutical treatment methods, and digital health systems with a focus on personalized cancer treatment and monitoring technologies

Person of Ordinary Skill (PHOSITA) Profile

A medical professional with advanced training in oncology, having expertise in pharmaceutical interventions, digital health technologies, data analytics, and personalized medicine approaches, with knowledge of emerging technologies in cancer treatment monitoring and drug delivery

Obviousness Rationale

A person having ordinary skill in the art would recognize that integrating digital monitoring technologies with established pharmaceutical treatments represents a predictable evolution of personalized medicine. The source patent's foundational method of melanoma treatment using dapansutrile provides a clear technological basis for exploring enhanced monitoring and delivery approaches. The PTD's proposed technological integrations represent logical extensions of existing medical technology trends toward precision medicine and data-driven treatment optimization.

Obvious Combinations & Variations

Source Patent Element
Method of administering dapansutrile for melanoma treatment
PTD Variation
AI-powered tumor monitoring module analyzing treatment response and providing personalized recommendations
Obviousness Reasoning
Predictable application of machine learning to medical treatment monitoring, representing a known technique for optimizing pharmaceutical interventions
Source Patent Element
Systemic administration of dapansutrile
PTD Variation
Nanomaterial-based targeted delivery system with stimuli-responsive release mechanism
Obviousness Reasoning
Known approach in pharmaceutical sciences to improve drug targeting and reduce systemic side effects, representing a finite set of predictable enhancement strategies
Source Patent Element
Treatment method for specific melanoma types
PTD Variation
Blockchain-based platform for tracking treatment outcomes and generating personalized insights
Obviousness Reasoning
Logical extension of medical record-keeping technologies to improve treatment tracking and personalization, utilizing standard data management techniques
Source Patent Element
Melanoma treatment using pharmaceutical intervention
PTD Variation
IoT-enabled wearable device with real-time dapansutrile level monitoring
Obviousness Reasoning
Predictable application of sensor technologies to pharmaceutical monitoring, representing a known approach in digital health monitoring
Source Patent Element
Method of reducing melanoma tumor size
PTD Variation
Genomic data analysis to identify genetic markers for personalized dapansutrile dosing
Obviousness Reasoning
Established approach in precision medicine to optimize pharmaceutical interventions based on individual genetic profiles
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857529 and the published technical disclosure, a person having ordinary skill in the art would find the proposed technological variations obvious and predictable extensions of existing melanoma treatment methodologies. The integration of AI, IoT, blockchain, and nanomaterial technologies with established pharmaceutical interventions represents a logical and non-inventive approach to enhancing personalized cancer treatment monitoring and delivery.

Original Patent Information

Patent NumberUS 11,857,529
TitleMethods for treating melanoma
Assignee(s)OLATEC THERAPEUTICS, INC.